PHARVARIS NV (PHVS) Stock Price & Overview
NASDAQ:PHVS • NL00150005Y4
Current stock price
The current stock price of PHVS is 28.56 USD. Today PHVS is down by -3.02%. In the past month the price increased by 10.53%. In the past year, price increased by 100%.
PHVS Key Statistics
- Market Cap
- 1.83B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.45
- Dividend Yield
- N/A
PHVS Stock Performance
PHVS Stock Chart
PHVS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is one of the better performing stocks in the market, outperforming 90.06% of all stocks.
PHVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHVS. While PHVS seems to be doing ok healthwise, there are quite some concerns on its profitability.
PHVS Earnings
PHVS Forecast & Estimates
19 analysts have analysed PHVS and the average price target is 47.31 USD. This implies a price increase of 65.66% is expected in the next year compared to the current price of 28.56.
PHVS Groups
Sector & Classification
PHVS Financial Highlights
Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS decreased by -20.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.31% | ||
| ROE | -52.43% | ||
| Debt/Equity | 0 |
PHVS Ownership
PHVS Latest News, Press Relases and Analysis
PHVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHVS
Company Profile
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Company Info
IPO: 2021-02-05
PHARVARIS NV
Emmy Noetherweg 2
Leiden ZUID-HOLLAND NL
CEO: Berndt Modig
Employees: 114
Phone: 31712036410
PHARVARIS NV / PHVS FAQ
Can you describe the business of PHARVARIS NV?
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
What is the current price of PHVS stock?
The current stock price of PHVS is 28.56 USD. The price decreased by -3.02% in the last trading session.
Does PHVS stock pay dividends?
PHVS does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHVS stock?
PHVS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PHVS stock listed?
PHVS stock is listed on the Nasdaq exchange.
What is the analyst forecast for PHVS stock?
19 analysts have analysed PHVS and the average price target is 47.31 USD. This implies a price increase of 65.66% is expected in the next year compared to the current price of 28.56.
When does PHARVARIS NV (PHVS) report earnings?
PHARVARIS NV (PHVS) will report earnings on 2026-05-11, after the market close.